<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850015</url>
  </required_header>
  <id_info>
    <org_study_id>CRC/2018/001</org_study_id>
    <nct_id>NCT03850015</nct_id>
  </id_info>
  <brief_title>High Frame Rate Ultrasound in Heart Disease Assessment</brief_title>
  <official_title>High Frame Rate Contrast Enhanced-ultrasound for the Assessment of Ischaemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London North West Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>London North West Healthcare NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare standard ultrasound images to high frame rate ultrasound images in&#xD;
      patients with heart disease or with a low risk of heart disease to see if a higher frame rate&#xD;
      of ultrasound adds to the information obtained from standard ultrasound.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following informed consent, patients recruited for the study will have an IV cannula inserted&#xD;
      and will undergo imaging using 2 ultrasound systems. Standard clinical system (Philips IE33)&#xD;
      will be used for 2D and CE imaging, followed by imaging using the Verasonics VantageTM&#xD;
      research system (Verasonics Inc., Redmond, WA), using both conventional 2D and HFR modes.&#xD;
&#xD;
      Baseline unenhanced 2D and Doppler images would initially be acquired using Philips IE33&#xD;
      system and Verasonics VatangeTM unenhanced conventional 2D and HFR mode .&#xD;
&#xD;
      Ultrasound contrast agent (Sonovue) will be then injected via the intravenous (iv) cannula&#xD;
      and 3 sets rest contrast images will be acquired - using the Phillips IE33, Verasonics and&#xD;
      Verasonics VantageTM platform (conventional CE and HFR CE). Both systems will be optimised&#xD;
      separately on each patient before and during infusion of contrast agent. When the optimal&#xD;
      imaging and destruction parameters are set, there are not modified along the acquisition.&#xD;
&#xD;
      This is followed by dipyridamole infusion and the scans being repeated during stress - 3 sets&#xD;
      contrast images will be acquired - using the Philips IE33 and Verasonics VantageTM platform&#xD;
      (conventional CE and HFR CE).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Agreement between HFR ultrasound and standard ultrasound.</measure>
    <time_frame>At 1 year</time_frame>
    <description>Demonstration that there is at least 80% agreement between HFR ultrasound techniques and standard techniques. Expressed as as a percentage of the recorded images.</description>
  </primary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Standard echocardiography</intervention_name>
    <description>Patients will undergo standard echocardiography, with and without contrast</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High frame rate echocardiography</intervention_name>
    <description>Following standard echocardiography, the test is repeated using high frame rate ultrasound</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        25 patients will be recruited over 12 months. 5 of these patients will be at low high of&#xD;
        having coronary artery disease and 20 at high risk of coronary artery disease. patients&#xD;
        will be recruited from those referred for clinical stress stress echocardiography.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria Either&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  age ≥18years and&#xD;
&#xD;
          -  confirmed inducible wall motion / perfusion abnormality on previous stress&#xD;
             echocardiogram&#xD;
&#xD;
          -  known coronary artery disease - defined by presence of flow-limiting coronary&#xD;
             stenosis(&gt;70% diameter stenosis) on coronary angiography.&#xD;
&#xD;
        OR&#xD;
&#xD;
        • patient who has been assessed as at low risk of having coronary heart disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to undertake pharmacological stress, ie previously known intolerance to&#xD;
             dipyridamole;&#xD;
&#xD;
          -  Moderate or Severe aortic or mitral regurgitation or severe mitral stenosis;&#xD;
&#xD;
          -  Significant pulmonary disease like severe COPD or pulmonary fibrosis;&#xD;
&#xD;
          -  Atrial fibrillation;&#xD;
&#xD;
          -  Inability to provide informed consent;&#xD;
&#xD;
          -  Pregnancy and lactation;&#xD;
&#xD;
          -  Known allergy to Sonovue&#xD;
&#xD;
          -  Patients with second and third degree heart block, unless they have a pacemaker fitted&#xD;
&#xD;
          -  Systolic BP &lt; 90&#xD;
&#xD;
          -  Known Myasthenia Gravis&#xD;
&#xD;
          -  Bronchial asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roxy Senior, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LONDON NORTH WEST UNIVERSITY HEALTHCARE NHS TRUST</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Banfield, BSc</last_name>
    <phone>+442088692547</phone>
    <email>annbanfield@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriel Bioh, MBBChir</last_name>
    <phone>+442088692547</phone>
    <email>gabriel.bioh@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>London North West University Healthcare NHS Trust</name>
      <address>
        <city>Harrow</city>
        <state>Middx</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Sunder Chita</last_name>
      <email>sunderchita@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Simon Lewis</last_name>
      <email>simon.lewis4@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual data will not be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

